BioSpace News Archive

Velan Capital, L.P. (together with the other participants in its solicitation, “Velan” or “we”), today issued a statement reminding stockholders that now is the time to demand accountability at Progenics and to follow the recommendation of Institutional Shareholder Services Inc.

Collaboration expands PTC’s Gene Therapy portfolio to rare ophthalmic diseases

Bluegrass.org, which has been providing comprehensive services to Central Kentuckians grappling with substance use, mental health issues and intellectual and developmental challenges since 1966, announced that the corporate name and branding has been changed to New Vista™.

Synergys Biotherapeutics, a preclinical stage biotherapeutics company developing Vasculogenic Mimicry (VM)-blocking antibody fusion drugs for cancer treatment announced today the granting of its second Phase 1 Small Business Innovation Research (SBIR) award by the National Cancer Institute (NCI)

The nation has reached a major milestone in its fight against the opioid epidemic, with more than half of all states requiring the use of electronic prescribing for opioids, controlled substances or all prescriptions.

Soleo Health, an innovative leader in specialty infusion services, announced today it ranked sixth among Dallas’ 50 Fastest-growing Middle Market Companies by the Dallas Business Journal.

Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the commercial launch in the United States of DEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg for the treatment of ocular inflammation and pain following ophthalmic surgery.

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for neratinib in combination with capecitabine for the treatment of patients with HER2-positive metastatic breast cancer who have failed two or more prior lines of HER2-directed treatments (third-line disease).

Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of May 10, ranking them by total market capitalization.

Expanded Role Strengthens Top Tier of Company’s Executive Leadership Team